Back to top
more

Allergan plc (AGN)

(Delayed Data from NYSE)

$145.81 USD

145.81
1,518,334

+1.56 (1.08%)

Updated May 3, 2019 04:01 PM ET

After-Market: $145.88 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Ironwood's Linzess Lowers Abdominal Symptoms in IBS-C Patients

by Zacks Equity Research

Ironwood (IRWD) and Allergan's Linzess meets the goal in a late-stage study for treating adult patients with IBS-C. Shares rise as the drug reduces bloating, pain and discomfort in IBS-C patients.

Biotech Stock Roundup: Amgen Gets FDA Nod for Kanjinti, Regeneron Presents Data

by Zacks Equity Research

Key highlights of the past week include regulatory approvals, collaborations and pipeline updates.

Amgen/Allergan Get FDA Nod for Herceptin Biosimilar Kanjinti

by Zacks Equity Research

FDA approves Amgen (AMGN) and Allergan's Kanjiniti, a biosimilar version of Roche's (RHHBY) breast cancer drug, Herceptin.

TherapeuticsMD Enters Agreement to Market Drugs Outside US

by Zacks Equity Research

TherapeuticsMD (TXMD) grants exclusive commercialization rights to its drugs, Bijuva and Imvexxy, to Theramex in ex-U.S. markets except for Canada and Israel.

Allergan (AGN) Down 9.7% Since Last Earnings Report: Can It Rebound?

by Zacks Equity Research

Allergan (AGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Ironwood Initiates Dosing in Mid-Stage Study for MD-7246

by Zacks Equity Research

Ironwood (IRWD)and its partner initiate dosing in a phase II study evaluating delayed-release version of Linzess, MD-7246, in patients with IBS-D.

Allergan's (AGN) Vraylar Gets FDA Nod for Bipolar Depression

by Zacks Equity Research

Allergan's (AGN) sNDA for Vraylar gets the FDA approval for the treatment of adult patients with major depressive episodes related to bipolar I disorder.

Conatus Down More Than 60% in the Past 90 Days: Here's Why

by Zacks Equity Research

Conatus' (CNAT) lead candidate, emricasan, developed for treating patients with fibrosis or cirrhosis caused by NASH misses the primary endpoint in two mid-stage studies that hits the stock massively.

Kinjel Shah headshot

Pharma Stock Roundup: AGN, NVO Report Q1 Earnings, NVS to Buy Takeda's Eye Drug

by Kinjel Shah

Allergan (AGN) and Novo Nordisk (NVO) announce Q1 results. Novartis buys rights to Takeda's dry eye disease drug, Xiidra.

Allergan (AGN) Beats on Q1 Earnings & Sales, Raises '19 View

by Zacks Equity Research

Allergan's (AGN) stock declines slightly in pre-market trading despite the company delivering earnings and revenue beat in the first quarter while marginally raising its guidance

Allergan (AGN) Q1 Earnings and Revenues Top Estimates

by Zacks Equity Research

Allergan (AGN) delivered earnings and revenue surprises of 6.76% and 2.04%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

Should You Buy Allergan (AGN) Ahead of Earnings?

by Zacks Equity Research

Allergan (AGN) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Why the Earnings Surprise Streak Could Continue for Allergan (AGN)

by Zacks Equity Research

Allergan (AGN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Ironwood (IRWD) Q1 Earnings & Revenues Miss, Shares Fall

by Zacks Equity Research

Ironwood (IRWD) misses on both earnings and sales in the first quarter. The company completes its separation into two entities.

    Teva (TEVA) Q1 Earnings Beat, Copaxone Drags Sales Down

    by Zacks Equity Research

    Teva Pharmaceutical (TEVA) beats estimates for earnings but misses the same for sales. Blockbuster drug Copaxone sales continue to erode amid generic competition.

    Can Allergan (AGN) Beat Earnings Estimates Again in Q1?

    by Zacks Equity Research

    Allergan's (AGN) key products like Botox are likely to provide top-line support in Q1 as loss of exclusivity of several products hurts sales

    Allergan (AGN) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release

    by Zacks Equity Research

    Allergan (AGN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

    Teva (TEVA) to Report Q1 Earnings: What's in the Cards?

    by Zacks Equity Research

    Pricing erosion in U.S. generics market and rapid erosion in sales of Copaxone are likely to hurt Teva's (TEVA) sales in Q1.

    Can Keytruda Drive Merck's (MRK) Q1 Earnings and Sales?

    by Zacks Equity Research

    Merck's (MRK) relatively newer products like Keytruda, Gardasil and Bridion are likely to drive first-quarter sales. However, genericization of key drugs and increasing competition are concerns.

    Is a Beat in Store for Editas (EDIT) This Earnings Season?

    by Zacks Equity Research

    On Editas' (EDIT) first-quarter earnings call, investor focus will be on the company's progress with its most advanced pipeline candidate, EDIT-101.

    Kinjel Shah headshot

    Pfizer (PFE) to Report Q1 Earnings: Will It Beat Estimates?

    by Kinjel Shah

    While Pfizer's (PFE) key drugs like Ibrance and Xeljanz are likely to drive Q1 sales, genericization of key drugs and weak sales in the EH segment will hurt.

    Kinjel Shah headshot

    Eli Lilly (LLY) to Report Q1 Earnings: What's in the Cards?

    by Kinjel Shah

    Eli Lilly and Company's (LLY) new drugs like Trulicity, Taltz and Jardiance are performing well. Let's see if these along with its older products lead to an earnings beat for the company in Q1.

    Gilead Collaborates With Insitro to Develop NASH Therapies

    by Zacks Equity Research

    Gilead (GILD) collaborates with data-driven company, Insitro, to harness the power of computers to discover and develop therapies for treating NASH (fatty liver).

    Allergan Falls as Supreme Court Dismisses Restasis Litigation

    by Zacks Equity Research

    Allergan's (AGN) key drug, Restasis' prospects hurt as the U.S. Supreme Court upholds the ruling of a lower court, which invalidated certain patents protecting the drug.

    Alkermes Reports Positive Data From Schizophrenia Study

    by Zacks Equity Research

    Alkermes (ALKS) reports positive top-line data from phase IIIb study evaluating Aristada and Invega Sustenna in patients with acute exacerbations of schizophrenia.